Background. Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that primarily affects adolescents and young adults. Patients can present with many peritoneal implants. We conducted a phase 2 clinical trial utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with cisplatin for DSRCT and pediatric-type abdominal sarcomas. Patients and Methods. A prospective cohort study was performed on 20 patients, who underwent CRS-HIPEC procedures, with cisplatin from 2012 to 2013. All patients were enrolled in the phase 2 clinical trial. Patients with extraabdominal disease and in whom complete cytoreduction (CCR0-1) could not be achieved were excluded. All outcomes were recorded. Results. Fourteen patients had DSRCT, while five patients had other sarcomas. One patient had repeat HIPEC. Patients with DSRCT had significantly longer median overall survival after surgery than patients with other tumors (44.3 vs. 12.5 months, p = 0.0013). The 3-year overall survival from time of diagnosis for DSRCT patients was 79 %. Estimated median recurrence-free survival (RFS) was 14.0 months. However, RFS for patients with DSRCT was significantly longer than for non-DSRCT patients (14.9 vs. 4.5 months, p = 0.0012). Among DSRCT patients, those without hepatic or portal metastases had longer median RFS than those with tumors at these sites (37.9 vs. 14.3 months, p = 0.02). In 100 % of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS-HIPEC. Conclusions. Complete CRS-HIPEC with cisplatin is effective in select DSRCT patients. DSRCT patients with hepatic or portal metastasis have poorer outcomes.
Patients and Methods. A prospective cohort study was performed on 20 patients, who underwent CRS-HIPEC procedures, with cisplatin from 2012 to 2013. All patients were enrolled in the phase 2 clinical trial. Patients with extraabdominal disease and in whom complete cytoreduction (CCR0-1) could not be achieved were excluded. All outcomes were recorded. Results. Fourteen patients had DSRCT, while five patients had other sarcomas. One patient had repeat HIPEC. Patients with DSRCT had significantly longer median overall survival after surgery than patients with other tumors (44.3 vs. 12.5 months, p = 0.0013). The 3-year overall survival from time of diagnosis for DSRCT patients was 79 %. Estimated median recurrence-free survival (RFS) was 14.0 months. However, RFS for patients with DSRCT was significantly longer than for non-DSRCT patients (14.9 vs. 4.5 months, p = 0.0012). Among DSRCT patients, those without hepatic or portal metastases had longer median RFS than those with tumors at these sites (37.9 vs. 14.3 months, p = 0.02). In 100 % of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS-HIPEC. Conclusions. Complete CRS-HIPEC with cisplatin is effective in select DSRCT patients. DSRCT patients with hepatic or portal metastasis have poorer outcomes.
Desmoplastic small round cell tumor (DSRCT) is an aggressive, rare form of sarcoma that primarily affects children, adolescents, and young adults. DSRCT is a malignancy for which the organ or tissue of origin is unknown. When diagnosed, dozens to hundreds of intraabdominal implants are identified throughout the peritoneal cavity. Five-year survival remains 15-25% despite multimodal treatment including chemotherapy, radiation therapy, and surgical resection. [1] [2] [3] DSRCT has a characteristic translocation (11;22p12;13q), resulting in a fusion protein joining EWS with WT1. It is this unique genetic fusion protein that distinguishes it from other sarcomas.
Previous reports have shown improved overall survival with aggressive surgical resection of all of the intraabdominal implants when combined with neoadjuvant and adjuvant chemotherapy and postoperative radiation. sarcomatosis, we hypothesized that hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) would be an effective local control tool to improve survival, as in adult carcinomatosis. 3, [5] [6] [7] [8] [9] We describe herein our results of a phase 2 study of CRS and HIPEC in pediatric, adolescent, and young adult aged sarcoma patients, most of whom had DSRCT. This research expands on phase 1 results demonstrating the safety of the CRS and HIPEC technique in the pediatric population. 10 
PATIENTS AND METHODS
From January 2012 through December 2013, accrual was met and 20 patients were enrolled. (None of these patients have been published elsewhere, except for one patient with granulosa cell tumor.) This was an investigator-initiated, single-institution, institutional review board (IRB)-approved protocol (IRB #2009-0528) at the University of Texas MD Anderson Cancer Center only. All operations were performed by two surgeons who specialize in HIPEC: one surgeon for those patients under 21 years of age, and another surgeon for those over age 21 years. Patients were included who were at least 1 year of age, had excellent performance status, had no liver or renal dysfunction, no cardiovascular contraindications to general anesthetic, and no detectable fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) imaging outside the abdominal cavity at time of CRS and HIPEC. Liver metastasis, if present, needed to be resectable at time of CRS and HIPEC, or without metabolic activity on PET at time of enrollment. All patients under age 21 years had DSRCT or other histologies of sarcomatosis. DSRCT was the only diagnosis for which adult patients were enrolled. All patients demonstrated response to neoadjuvant chemotherapy with at least 4 months of prior chemotherapy. Chemotherapy regimens varied, but all chemotherapies were those commonly used to treat Ewing's sarcoma. Patients were not eligible unless at least partial response (PR) to chemotherapy was identified by cross-sectional imaging. All DSRCT patients underwent postoperative whole-abdominal radiation therapy (WART), while rhabdomyosarcoma (RMS) patients, who had previous abdominal or pelvic radiation therapy, did not.
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Among the 20 patients enrolled, one patient enrolled twice. This patient enrolled in the study again after recurrence following the first CRS-HIPEC procedure. The patient had a recurrence after the second procedure and succumbed. In our analysis, for the first procedure, overall survival was calculated from date of diagnosis to one day before date of second surgery, the patient was censored, and RFS time was calculated as time from date of first surgery to date of first recurrence. For the second procedure, overall survival was calculated from date of second surgery to date of death, and RFS time was calculated as time from date of second surgery to date of second recurrence. Clinical factors and age at time of each surgery were included in the analysis. We treated the two enrollments as two independent patients in our analysis; no within-patient association was adjusted. However, we performed a sensitivity analysis by excluding this patient's second enrollment. The sensitivity analysis revealed that exclusion of the second enrollment had no significant effect on comparisons of overall survival or recurrent-free survival between patients with DSRCT and those with other histologies.
The peritoneal carcinomatosis index as described by Sugarbaker was calculated at time of abdominal exploration. 12 
Complete
(CR0) or near-complete (CR1 = \ 2.5 cm of tumor remaining) cytoreduction was achieved before HIPEC. Standard peritonectomy technique was used. All patients underwent closed-technique HIPEC using 100 mg/m 2 cisplatin for 90 min at 41°C. Nephroprotection was employed in all patients. Specifically, preoperatively patients were admitted the day before for continuous intravenous hydration. In the operating room, a bolus of intravenous sodium thiosulfate was delivered beginning 30 min into the 90-min perfusion, followed by continuous infusion for 12 h. This was followed by postoperative delivery of 1.5 times maintenance intravenous fluids and replacement of all fluid losses. This regimen, and the advantages of vigorous pre-, intra-, and postoperative hydration in this setting, was previously published by our group. 10 To verify intraperitoneal temperatures, four fiberoptic temperature probes were sutured to the peritoneum in the following positions: right abdominal wall, left abdominal wall, sigmoid colon mesentery in the pelvis, and ligament of Treitz. As a control for core body temperature, a needle temperature probe was placed in the right lobe of the liver to verify the core temperature. These probes were connected to a standard computer, giving a constant reading of the temperature in each area for the duration of the 90-min HIPEC.
Types of operations performed during CRS included peritonectomy, small and large bowel resections with primary anastomosis, pelvic tumor and rectal resection without colostomy, partial diaphragm resection and primary closure, resection of the pelvic tumor and pouch of Douglas, distal pancreatectomy, and splenectomy.
Portal disease was defined as nodal, and/or a plaque-like 1-2-mm-thick sheet of tumor at the porta hepatis. Portal node dissection was completed when nodal enlargement was encountered. However, plaque-like disease was dissected distally up to the confluence of the liver edge.
Descriptive statistics and tabulation were used to summarize the data. Overall survival time was calculated from date of surgery to date of death or date of last follow-up for patients alive. Recurrence-free survival was calculated as time from date of surgery to date of death or date of recurrence whichever occurred first for patients who experienced an event, and to date of last follow-up for patients alive without recurrence. The Kaplan-Meier method was used to estimate the probability of recurrencefree survival and overall survival. 13 The log-rank test and Cox model were applied to determine the association between relapse-free survival (RFS) or overall survival (OS) and patient characteristics. Variables with p value \ 0.05 were considered statistically significant. S-Plus software v8.2 (TIBCO Software Inc., Palo Alto, CA) was used for data analysis.
RESULTS
Patients were aged 23 months to 50 years. Data were evaluated for 36 months after the last enrollee. Median follow-up time for all enrolled patients was 44.6 months. Twenty-two patients were consented on the protocol. Two patients could not be completely cytoreduced and therefore were not enrolled. There were no protocol violations. All 20 enrolled patients completed the protocol. Among these 20 patients, 14 had DSRCT, 2 RMS, 2 undifferentiated sarcomas, 1 juvenile granulosa cell tumor with sarcomatous elements, and 1 Ewing's sarcoma. There were 14 males and 6 females. All but one of the DSRCT patients were male. Median patient age was 20.8 years. Median peritoneal carcinomatosis index (PCI) was 15 (highest 37). Three patients had liver metastasis, which was resected at time of HIPEC. All patients had complete cytoreduction (CCR0-1).
There was no association of age or PCI to overall or relapse-free survival on multivariate analysis. The estimated median RFS duration for the 20 patients was 13.99 months [95% confidence interval (CI) 7.26 months to not achieved (NA)]. The estimated 3-year overall survival rate from diagnosis was 83% (95% CI 67-100%) (Fig. 1a, b) . When divided by histology, DSRCT patients had longer RFS time (median 14.87 months with 95% CI of 13.99 months to NA) than patients with other histologies (median 4.5 months with 95% CI of 2.96 months to NA) (p = 0.0012, Fig. 2a) . Similarly, DSRCT patients had longer OS following surgery (median 44.32 months with 95% CI of 34.53 months to NA) than patients with other histologies (median 12.52 months with 95% CI of 11.47 months to NA) (p = 0.0013, Fig. 2B ). From time of diagnosis for DSRCT patients, the estimated median OS was 58.44 months (95% CI 40.14 months to NA), and the estimated 3-year OS was 79% (95% CI 0.6-1).
Among the 14 patients with DSRCT, 8 patients had hepatic or portal disease, while 6 patients had neither hepatic nor portal disease. In the patients without liver or portal disease, there were two recurrences: one patient developed intrahepatic and pulmonary metastases, while the other patient recurred within his inguinal lymph nodes. We observed no peritoneal-based recurrences in these six patients. In contrast, 87.5% (7/8) of patients with intrahepatic or portal disease eventually developed intraabdominal recurrence, with four being intrahepatic and three being peritoneal. However, there were no recurrences in patients with portal disease. All of the liver recurrences were parenchymal. In addition, DSRCT patients without intrahepatic, portal, or distant disease had a significantly longer disease-free interval (37.9 vs. 14.3 months, p = 0.02) than those who did have intrahepatic or portal disease at time of CRS-HIPEC. Two of the six patients without intrahepatic or portal disease died, one from liver failure unrelated to his disease and one due to developing intrahepatic and pulmonary metastases. Five of the eight patients with hepatic or portal disease died, all of which were attributed to recurrent peritoneal or hepatic disease. There was no significant difference in OS between patients who did and did not have intrahepatic or portal disease at time of CRS-HIPEC (p = 0.34).
There were no deaths or serious adverse events (SAEs) related to cytoreductive surgery and HIPEC (perioperative). Two patients had a total of two grade 4 adverse events (AEs). Both were elevation of creatinine of more than 1.5 times normal that spontaneously resolved within 2 weeks of HIPEC. Of 35 AEs possibly or probably related to the study drug delivery at HIPEC, 16 were spontaneously resolved grade 1-3 leukopenia or thrombocytopenia. At 30 days post-HIPEC, seven patients had no complications. Major postoperative complications occurred in eight patients (40%): three patients had temporary neurogenic bladder, two developed urinary tract infections and a wound infection, and abscess and enterocutaneous fistula each occurred in one patient. The patient who developed an enterocutaneous fistula had previously been treated with high-dose abdominal radiation therapy. DISCUSSION DSRCT is a rare, highly aggressive sarcoma subtype that usually presents with massive tumor burden spread throughout the abdomen. Our phase 2 clinical trial results indicate that aggressive surgical therapy such as CRS and HIPEC with WART led to improved disease control and short-term survival in a highly selected subset of patients when combined with coordinated multidisciplinary care. These results reflect the ability of CRS, HIPEC, and WART to provide effective local control of DSRCT. Of patients without liver disease, 100% had no peritonealdisease recurrence after CRS, HIPEC, and WART within the observed follow-up period. All of these patients had substantial reduction in tumor volume with neoadjuvant chemotherapy. All had postoperative radiation and adjuvant chemotherapy.
As demonstrated in this manuscript, at approximately 3 years post-CRS, HIPEC, and WART, extraabdominal recurrences are seen, as is recurrent liver disease, even in patients in whom liver disease was quiescent by PET or resected at time of HIPEC. Extraperitoneal recurrences persist despite long-term local control from CRS, HIPEC, and WART. To that effect, 33% (2/6) of DSRCT patients without liver or portal disease eventually developed disease within the inguinal lymph nodes, lung and liver parenchyma, despite the fact that they never developed a peritoneal recurrence. This highlights the need for improved systemic chemotherapies for DSRCT and that the local control from CRS, HIPEC, and WART appears to be effective.
In this report, all patients had complete cytoreduction, likely contributing to the 79% 3-year OS and estimated median OS of 58.4 months in DSRCT. In previous reports, of CRS and HIPEC in DSRCT, we noted a difference in median survival of 26.7 months compared with 63.4 months when incomplete or complete cytoreduction, respectively, was done with HIPEC. 9 Other authors have shown that, in colon cancer and appendiceal carcinomatosis, complete cytoreduction improves survival. 8, 14, 15 Complete cytoreduction is a critical component to the success of CRS and HIPEC in DSRCT. 16, 17 Complete cytoreduction impacts short-term outcome, but long-term survival remains a challenge due to lack of completely effective chemotherapy to address microscopic systemic disease.
In a report by Gil et al., median survival for DSRCT patients was 18 months. 18 In that report, as well as the current study, complete or near-complete cytoreduction was achieved. However, the main difference was lack of coordinated neoadjuvant and adjuvant chemotherapy and radiotherapy in the Gil report. P6 induction chemotherapy, surgical debulking, and radiotherapy. 17 Similarly, gross tumor resection was highly significant in prolonging overall survival (p \ 0.00001). HIPEC was not employed in that study. By comparison, we observed 79 % 3-year overall survival when adding HIPEC to the same multimodal treatment regimen employed by Lal and colleagues. Thus, HIPEC remains an intriguing local control strategy that may help prolong survival in DSRCT patients.
Most recently, Honorè et al. reviewed 48 DSRCT patients who underwent CRS, including 11 patients who received intraperitoneal chemotherapy. 19 Median overall survival was 42 months and was not significantly increased with intraperitoneal chemotherapy. However, there was nonuniform utilization of neoadjuvant chemotherapy (77%), adjuvant chemotherapy (79%), postoperative WART (48%), as well as intraperitoneal chemotherapy in that study. In addition, there was widespread heterogeneity amongst the chemotherapeutic agents employed for intraperitoneal treatment for those patients. Of the 11 patients receiving intraperitoneal chemotherapy, only four underwent HIPEC with cisplatin. Cisplatin is the preferred HIPEC drug in sarcoma.
It is unclear why patients with diagnoses other than DSRCT had poorer outcomes after surgery, even with complete cytoreduction. Perhaps a different drug other than cisplatin is necessary. We hypothesize that these other sarcoma histologies are less responsive to cisplatin chemotherapy. In addition, these were, in general, more heavily pretreated patients who had sustained two or more relapses and recurrences. It is important to note that HIPEC has not been found to be effective in other sarcomas of adults. [20] [21] [22] The Ewing's type biology of DSRCT may make it more sensitive to chemotherapy and radiation therapy, compared with other sarcomas, which perhaps is the explanation. Given these results, we have now initiated a phase 1 trial utilizing HIPEC with doxorubicin for pediatric patients with non-DSRCT sarcomas at our institution.
A limitation of this phase 2 trial is the fact that it was nonrandomized. Therefore, one cannot decipher the relative contribution to improved outcome from complete surgical excision of intraabdominal implants, versus with the addition of hyperthermic intraperitoneal cisplatin. Similar outcomes may or may not be obtained with complete CRS, without HIPEC.
CONCLUSIONS
The results of this phase 2 trial show that complete CRS, HIPEC, and WART are an effective local control therapy in DSRCT patients. More effective chemotherapy is necessary to improve long-term outcomes.
